Life Science Company News

Reset
Results 1 - 20 out of 500 displayed.
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25 »

Dialogue with CGT Leaders! You Are Invited to Join the "2024 GenScript Biotech Global Forum•London" to Discuss the Future Together

Read more ››
By: PR Newswire Association LLC. - 15 Sep 2024

RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer

Read more ››
By: PR Newswire Association LLC. - 14 Sep 2024
Related companies:  Johnson & Johnson, Inc.

KFSHRC Revolutionizes Patient Care with Pioneering Experience Ambassadors Program

Read more ››
By: GlobeNewswire - 14 Sep 2024

Medigene Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024

Read more ››
By: GlobeNewswire - 14 Sep 2024

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

Read more ››
By: PR Newswire Association LLC. - 14 Sep 2024
Related companies:  Jiangsu Simcere Pharmaceutical Co., Ltd.

Adela Announces Clinical Validation Results for Head & Neck Cancer MRD Test Simultaneously Published in Annals of Oncology and Presented at ESMO 2024

Read more ››
By: PR Newswire Association LLC. - 14 Sep 2024
Related companies:  Adela, Inc.

SOPHiA GENETICS Presents Ground-Breaking Multimodal Research on AI-Driven Patient Stratification at ESMO 2024

Read more ››
By: PR Newswire Association LLC. - 14 Sep 2024
Related companies:  SOPHiA GENETICS SA

Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)

Read more ››
By: PR Newswire Association LLC. - 14 Sep 2024

iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

Read more ››
By: GlobeNewswire - 14 Sep 2024
Related companies:  iTeos Therapeutics, Inc.

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

Read more ››
By: GlobeNewswire - 14 Sep 2024
Related companies:  IO Biotech, Inc.

Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors

Read more ››
By: GlobeNewswire - 14 Sep 2024
Related companies:  Avacta Group plc

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer

Read more ››
By: GlobeNewswire - 14 Sep 2024
Related companies:  Immunocore Limited

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

Read more ››
By: GlobeNewswire - 14 Sep 2024
Related companies:  Sutro Biopharma, Inc.

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

Read more ››
By: GlobeNewswire - 14 Sep 2024
Related companies:  Black Diamond Therapeutics Inc.

Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024

Read more ››
By: GlobeNewswire - 14 Sep 2024
Related companies:  Cullinan Therapeutics, Inc.

RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer

Read more ››
By: PR Newswire Association LLC. - 14 Sep 2024
Related companies:  Johnson & Johnson, Inc.

Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines

Read more ››
By: PR Newswire Association LLC. - 14 Sep 2024
Related companies:  Nuvalent, Inc.

Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024

Read more ››
By: PR Newswire Association LLC. - 14 Sep 2024

Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation

Read more ››
By: PR Newswire Association LLC. - 14 Sep 2024
Related companies:  Ascentage Pharma

Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.

Read more ››
By: GlobeNewswire - 14 Sep 2024
Results 1 - 20 out of 500 displayed.
1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25 »

Enhance your business development with Biotechgate
Try for free »